EUVIMEDEUVIMED entdecken
EditorialOpen Access · CC BY 4.0

A remarkable year for NSCLC: Seven new FDA approvals in 2025 across molecular targets

Krešimir Tomić, Semir Vranić

Biomolecules and Biomedicine · 2026

DOI: 10.17305/bb.2026.13832 ↗

Kurz gefasst

Editorial in der Zeitschrift Biomolecules and Biomedicine, 2026. Verfasst von Krešimir Tomić und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, University Hospital Center Mostar, Mostar, Bosnia and Herzegovina. Hauptthemen laut MEDLINE: Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Drug Approval, Lung Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Non-small cell lung cancer (NSCLC) remains the leading cause of cancer mortality worldwide; however, precision oncology has fundamentally transformed its treatment landscape. In 2025, seven approvals by the U.S. Food and Drug Administration (FDA) further accelerated biomarker-driven care across critical molecular subsets. These include MET-directed and trophoblast cell-surface antigen-2 (TROP-2) antibody-drug conjugates (ADCs), expanded strategies targeting epidermal growth factor receptor (EGFR), notably those addressing exon 20 insertion mutations, a ROS proto-oncogene 1 (ROS1) inhibitor, and various human epidermal growth factor receptor 2 (HER2) options that encompass both tumor-agnostic and mutation-selected approaches. These advancements underscore the necessity for integrated diagnostics—such as next-generation sequencing (NGS), fluorescence in situ hybridization (FISH), and immunohistochemistry (IHC)—while also emphasizing ongoing challenges in biomarker selection, therapeutic sequencing, and equitable global implementation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsCarcinoma, Non-Small-Cell LungDrug ApprovalLung NeoplasmsHumansBiomarkers, TumorErbB ReceptorsMolecular Targeted TherapyProto-Oncogene MasUnited StatesUnited States Food and Drug Administration

Substanzen

Antineoplastic AgentsBiomarkers, TumorErbB ReceptorsMAS1 protein, humanProto-Oncogene Mas

Autor:innen und Institutionen

  • Department of Oncology, University Hospital Center Mostar, Mostar, Bosnia and Herzegovina.
  • College of Medicine, QU Health, Qatar University, Doha, Qatar.

Zitieren

APA

Tomić, K., & Vranić, S. (2026). A remarkable year for NSCLC: Seven new FDA approvals in 2025 across molecular targets. Biomolecules and Biomedicine. https://doi.org/10.17305/bb.2026.13832

Vancouver

Tomić K, Vranić S. A remarkable year for NSCLC: Seven new FDA approvals in 2025 across molecular targets. Biomolecules and Biomedicine. 2026. doi:10.17305/bb.2026.13832

BibTeX
@article{Tomi2026,
  author = {Tomić, Krešimir and Vranić, Semir},
  title = {A remarkable year for NSCLC: Seven new FDA approvals in 2025 across molecular targets},
  journal = {Biomolecules and Biomedicine},
  year = {2026},
  doi = {10.17305/bb.2026.13832}
}
Kostenlos starten →